FDA Confirm WAP Sensual Enhancement Has Four Undeclared Drugs Key

Undeclared active pharmaceutical ingredients in a commercially available sexual enhancement product have drawn a second FDA advisory, reinforcing the agency's sustained enforcement focus on API traceability and label integrity across the supplement and quasi-pharmaceutical space. FDA laboratory analysis of WAP Sensual Enhancement confirmed the presence of sildenafil, tadalafil, flibanserin, and yohimbine, none disclosed on the product label, with updated August 2026 testing identifying yohimbine at levels the agency characterizes as dangerously elevated.

For QA directors and regulatory affairs leads, the case illustrates a recurring adulteration pattern: products marketed as dietary supplements or natural formulations concealing prescription-only APIs. Sildenafil and tadalafil are the active ingredients in FDA-approved prescription drugs Viagra and Cialis, respectively, and carry contraindication risk when combined with nitrates commonly prescribed for cardiovascular conditions. Flibanserin, the active ingredient in Addyi, presents compounding risk through hypotensive effects, particularly when combined with alcohol. Yohimbine at high concentrations introduces cardiovascular and neuropsychiatric risk profiles that extend to patients on MAOIs, stimulants, and certain antidepressants.

The enforcement pattern here is instructive for legitimate manufacturers operating under 21 CFR Part 211. FDA's inability to test every product in this category, acknowledged explicitly in the advisory, places upstream pressure on supply chain controls, API sourcing documentation, and finished-product specification testing. For facilities handling APIs that appear in adulteration cases, the reputational and regulatory exposure from supply chain gaps is not hypothetical. Robust incoming material verification and vendor qualification protocols remain the primary line of defense against inadvertent association with tainted supply chains.

The product was identified as available through eBay and retail store channels, with FDA testing conducted across multiple sample batches from retail locations. Adverse events linked to the product should be submitted through FDA's MedWatch voluntary reporting program, either via the online form or by fax to 1-800-FDA-0178.

The August 2026 update, which added yohimbine to the confirmed ingredient list, signals that FDA's laboratory surveillance on this product is ongoing, and further sample testing remains possible as distribution channels are identified.

Source: U.S. Food and Drug Administration, Medication Health Fraud Notifications, via FDA.gov, August 25, 2026.